MICOT PHARMA-B (02335) rose more than 5% during intraday trading, with shares up 4.42% as of press time at HK$21.72, on turnover of HK$1.4386 million.

MICOT PHARMA-B announced that, according to notices separately issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange on September 4, 2026 and September 7, 2026, the company's H shares have been included in the list of eligible shares under the Stock Connect mechanism (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect), effective from September 7, 2026. Following the inclusion of the shares in the Stock Connect mechanism, qualified mainland Chinese investors may trade the shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange.

Previously, MICOT PHARMA-B announced that the Phase II clinical trial of MT200605, a drug candidate independently developed by the group for the treatment of acute ischemic stroke, has been completed. The clinical trial has demonstrated significant and robust efficacy advantages as well as a favorable safety profile.